Stebbing, Justin
Baranau, Yauheni http://orcid.org/0000-0003-4582-5615
Baryash, Valery
Moiseyenko, Vladimir
Boliukh, Dmytro
Antone, Nicoleta
Manikhas, Alexey
Chornobai, Anatolii
Park, Taehong http://orcid.org/0000-0003-1922-2810
Baek, Eric Hyungseok http://orcid.org/0000-0002-7286-7215
Lee, Jaeyong
Choi, Jiin
Kim, Nahyun
Ahn, Keumyoung http://orcid.org/0000-0002-9370-5338
Lee, Sang Joon http://orcid.org/0000-0001-9897-2163
Kim, Sunghyun
Funding for this research was provided by:
Celltrion
Article History
Accepted: 19 January 2023
First Online: 7 March 2023
Declarations
:
: This study was funded by Celltrion, Inc. (Incheon, Republic of Korea).
: Justin Stebbing has received consulting fees or honoraria (2020–present) from Agenus, Alveo Technologies, APIM Therapeutics, Benevolent AI, Bryologyx, Celltrion, Certis, Eli Lilly, Equilibre Biopharmaceuticals, Graviton Bioscience Corporation, Greenmantle, Heat Biologics, IO Labs, Onconox, Pear Bio, Vaccitech, Volvox, vTv Therapeutics, and Zephyr AI; he has consulted with Lansdowne Partners and Vitruvian; he chairs the Board of Directors for Xerion and previously BB Biotech Healthcare Trust PLC; and is Editor-in-Chief of <i>Oncogene</i>. Taehong Park, Jaeyong Lee, Jiin Choi, Nahyun Kim, Keumyoung Ahn, Sang Joon Lee and Sunghyun Kim are employees of Celltrion, Inc. and hold stock in Celltrion, Inc. Eric Hyungseok Baek is an employee of Celltrion, Inc. Yauheni Baranau, Valery Baryash, Vladimir Moiseyenko, Dmytro Boliukh, Nicoleta Antone, Alexey Manikhas and Anatolii Chornobai have no conflicts of interest to disclose.
: All data generated or analysed during this study are included in this published article and its Online Supplementary Material.
: Not applicable.
: Justin Stebbing, Taehong Park, Eric Hyungseok Baek, Keumyoung Ahn, Sang Joon Lee, and Sunghyun Kim contributed to study design and data analysis or interpretation. Yauheni Baranau, Valery Baryash, Vladimir Moiseyenko, Dmytro Boliukh, Nicoleta Antone, Alexey Manikhas, and Anatolii Chornobai contributed to data collection. Jaeyong Lee, Jiin Choi, and Nahyun Kim contributed to data analysis or interpretation. All authors reviewed and critically revised drafts of the manuscript, approved the version to be published, and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
: The study was conducted in accordance with the ethical principles originating in the Declaration of Helsinki, Good Clinical Practice, and all applicable laws or regulations. Before the start of the study, the protocol, informed consent form, advertisements to be used for the recruitment of study patients, and any other written information to be provided to the patients were approved by the institutional review board and/or independent ethics committee at each site (Table S1, OSM Resource 1).
: Written informed consent was obtained from all individual participants included in the study.
: All participants provided consent for their data to be published.
: Selected data from the CT-P6 4.2 study were presented at the European Society for Medical Oncology (ESMO) Breast Cancer Congress (3–5 May 2022).